Impact of the 13-valent pneumococcal conjugate vaccine (pcv13) on invasive pneumococcal disease and carriage in Alaska
Impact of the 13-valent pneumococcal conjugate vaccine (pcv13) on invasive pneumococcal disease and carriage in Alaska
复制标题
DOI：
10.1016/j.vaccine.2015.07.080
复制
发表时间：
2015-09-11
期刊：
影响因子：
5.5
通讯作者：
Hennessy, Thomas
中科院分区：
文献类型：
--
作者：
Bruce, Michael G.;Singleton, Rosalyn;Hennessy, Thomas
Background: Alaska Native (AN) children have experienced high rates of invasive pneumococcal disease (IPD). In March 2010, PCV13 was introduced statewide in Alaska. We evaluated the impact of PCV13 on IPD in children and adults, 45 months after introduction.Methods: Pneumococcal sterile site isolates, reported through state-wide surveillance, were serotyped using standard methods. We defined a pre-PCV13 time period 2005-2008 and post-PCV13 time period April 2010-December 2013; excluding Jan 2009-March 2010 because PCV13 was introduced pre-licensure in one high-risk region in 2009.Results: Among Alaska children
